智通财经APP获悉，瑞银发布研报称，首次覆盖固生堂(02273)给予买入评级和目标价48.30港元，对应 20倍/17倍2025 年/2026年预测市盈率/经调整盈利，以及0.9倍2026年预测市盈增长比率 (PEG)。考虑到 其强劲的增长前景和较低的估值，固生堂是该行在医疗健康服务领域的首选标的。潜在的催化剂包括： 持续强劲的盈利增长、诊所快速扩张，以及在院内制剂、人工智能技术和海外扩张方面的进展。 报告指，固生堂为中医师建立了一个可持续且回报丰厚的职业发展平台，在增加医师覆盖率和提升其生 产力方面存在显著机遇。除了在中医药供应链、人才资源和技术方面的优势，固生堂还在拓展其自费增 值业务以应对政策风险。长期来看，该行认为在 DRG/DIP 等支付方式改革后，高层级公立医院可能被 激励将慢性病患者向下转诊。固生堂凭借其专注于慢性病、贴近城市社区以及差异化和高质量的产品/ 服务，定位良好，有望从中受益，在承接公立医院慢性病患者方面的长期机遇。该行预测固生堂在 2024-2027 年期间能够维持20%的经调整盈利复合年增长率 (CAGR)(Visible Alpha 共识预期为 19%)，增 长可见性强。 ...

Core Viewpoint - UBS has initiated a "Buy" rating for Guoshengtang with a target price of HKD 48.3, forecasting a compound annual growth rate (CAGR) of 20% for adjusted earnings from 2024 to 2027 [1] Summary by Relevant Categories Company Growth Potential - UBS believes that investors may underestimate Guoshengtang's advantages in attracting doctors, managing policy risks, and serving chronic disease patients from public hospitals [1] - The company's sustainable growth is supported by its expertise in traditional Chinese medicine and value-added services [1] Market Opportunities - There are favorable opportunities for Guoshengtang to enhance doctor coverage and productivity [1] - The company is expanding its self-paid value-added services by leveraging its strengths in the traditional Chinese medicine supply chain, talent, and technology to mitigate policy risks [1]

Core Viewpoint - UBS initiates coverage on Guoshengtang (2273.HK) with a "Buy" rating and a target price of HKD 48.3, corresponding to a 17x projected P/E ratio for 2026 [1] Group 1: Financial Projections - UBS forecasts a compound annual growth rate (CAGR) of 20% for adjusted earnings from 2024 to 2027, surpassing the market average expectation of 19% [1] - The firm highlights strong visibility in Guoshengtang's growth prospects, supported by favorable valuation and limited policy risks [1] Group 2: Competitive Advantages - Guoshengtang's ability to attract and retain doctors is emphasized as a significant advantage, along with its capacity to manage policy risks and long-term opportunities from public hospitals treating chronic disease patients [1] - The company is building a sustainable and rewarding career development platform for traditional Chinese medicine, which is expected to enhance doctor coverage and productivity [1] Group 3: Market Opportunities - UBS notes that Guoshengtang is actively expanding its self-paid value-added services to mitigate policy risks, leveraging its strengths in the traditional Chinese medicine supply chain, talent resources, and technology [1] - Long-term, Guoshengtang is positioned to benefit from the trend of public hospitals referring chronic disease patients downwards, aided by its focus on chronic diseases and proximity to urban communities [1]

2025开年以来港股市场表现活跃，主要指数涨势喜人。公募机构对港股的关注度显著提升，不仅主 动权益类基金、QDII基金积极布局港股，一些"固收+"基金也大举配置港股，向港股市场要收益。数据 显示，多只"固收+"基金对港股的持仓接近了合同规定的港股投资比例上限，得益于"纯债资产打底""港 股红利防御"和"科技龙头增厚"的三重配置优势，这些"固收+"基金近期普遍取得了不错的业绩。 "固收+"产品含"港"量提升 2025开年以来，港股市场表现亮眼。Wind数据显示，截至3月20日，恒生指数和恒生科技指数年内 涨幅分别超过20%和30%。 港股市场的潜在上行空间吸引了主动权益类基金和QDII基金的关注，截至去年底，在港交所挂牌 的腾讯控股成为公募基金第二大重仓股，小米集团、中芯国际等港股标的也成为公募基金增持较多的品 种；QDII基金也日益展现出配置重点转向港股的趋势。 "固收+"基金同样也在投资范围内积极配置港股。数据显示，截至去年底，全市场二级债基合计持 有的港股市值达到54.2亿元。从基金管理人来看，二级债基港股持仓市值最高的是广发基金，旗下相关 产品合计持有港股市值达7.89亿元。 从单只基金来看，7只二级债 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | 公司名稱: 固生堂控股有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 264,430,287 | USD | | 0.0001 | USD | | 26,443.03 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 264,430,287 | USD | | 0.0001 | USD | | 26,443.03 | 本月底法定/註冊股本總額： USD 26,443.03 ...

国金证券研报指出，固生堂于2025年8月1日正式发布了10个"国医AI分身"，涵盖肿瘤科、皮肤科、消化 内科等8个中医专科领域。 "国医AI分身"的应用价值在于：协助专家处理常规诊疗事务，提高顶尖专家的诊疗效率，理论上可将专 家生产力提升5倍以上；通过智能辅助，帮助青年医生掌握名医诊疗思维，缩短其成长周期。AI分身基 于30年以上诊疗经验的名中医海量高质量数据生成，专家模拟一致性达86%以上，辨证准确性和用药合 理性获得专家高度评价。 国金证券预测固生堂2025—2027年归母净利润分别为4.27/5.50/7.04亿元，同比增长39%/29%/28%，EPS 分别为1.81/2.33/2.98元，对应PE为20/15/12倍，维持"买入"评级。 ...

Core Insights - Gushengtang has made significant advancements in the AI sector, launching its first "National Medicine AI Avatar" on June 7 and subsequently releasing 10 additional avatars on August 1, covering eight core specialties in traditional Chinese medicine (TCM) [1][3] - The expansion of the "National Medicine AI Avatar" is a crucial step in Gushengtang's ongoing "TCM + AI" strategy, establishing a solid foundation for the commercialization of TCM AI [1][4] AI Avatar Development - The 10 newly released "National Medicine AI Avatars" are based on the clinical experiences of ten renowned doctors, ensuring that the system aligns closely with expert decision-making processes [3][9] - The application of the AI avatars enhances efficiency by assisting experts with routine diagnostic tasks, allowing them to focus on critical decision-making, and also aids junior doctors in mastering expert diagnostic thinking [3][4] Commercialization Strategy - Gushengtang has integrated commercialization logic into the development of the AI avatars, targeting the "online follow-up" service to address the scarcity of quality TCM resources and the high demand for expert consultations [4][10] - The "online follow-up" service has shown promising commercial prospects, with significant user acceptance and efficiency improvements reported by both patients and doctors [7][10] Technical Innovation - Gushengtang has established a replicable path for creating expert digital avatars, utilizing a comprehensive data processing chain to efficiently leverage diverse data sources [8][9] - The company has developed a robust technical framework that supports the AI avatars in assisting doctors throughout the entire TCM diagnostic process, creating a closed-loop system for AI-assisted diagnosis [8][9] Future Growth Potential - Gushengtang aims to expand its expert roster and enhance its AI avatar offerings, creating a collaborative AI internet ecosystem in TCM to provide quality services to more patients [7][10] - The company plans to drive growth through continuous technological innovation and business model enhancements, focusing on improving patient experience and optimizing treatment outcomes [10]

Core Viewpoint - The company, Gushengtang, has made significant advancements in the AI field this year, particularly with the launch of its "National Medicine AI Avatar" initiative, which aims to integrate traditional Chinese medicine with AI technology to enhance healthcare delivery and efficiency [1][3]. Group 1: AI Development and Implementation - Gushengtang released 10 new "National Medicine AI Avatars" on August 1, covering eight core specialties in traditional Chinese medicine, marking a major step in its "Traditional Medicine + AI" strategy [1][2]. - The AI avatars are built on the clinical experiences of ten renowned doctors, ensuring that the system aligns closely with expert decision-making processes [2][12]. - The application of the AI avatars is twofold: assisting experts in routine tasks to focus on critical decisions and aiding young doctors in mastering diagnostic thinking, thereby shortening their learning curve [2][3]. Group 2: Commercialization and Market Impact - The "National Medicine AI Avatar" has successfully addressed the commercialization challenges faced by medical AI by introducing an "online follow-up" service, which alleviates the scarcity of quality traditional Chinese medicine resources [3][9]. - Initial data indicates that the AI avatar service has been well-received, with significant patient engagement within two weeks of launch, demonstrating its potential to enhance expert productivity by over five times [9][10]. - Gushengtang plans to expand its roster of expert avatars and create a collaborative AI ecosystem in traditional Chinese medicine, aiming to make quality healthcare more accessible [9][13]. Group 3: Technological Innovation and Infrastructure - The company has established a replicable path for creating expert digital avatars, utilizing a comprehensive data processing chain to efficiently leverage diverse data sources [10][11]. - Gushengtang's AI model foundation and multi-agent intelligent systems create a robust technical barrier in the industry, enabling a complete closed-loop process for traditional Chinese medicine AI diagnosis [11][12]. - Collaborations with leading AI firms and research institutions, such as Huawei and Tsinghua University, have strengthened Gushengtang's AI capabilities and ecosystem [12][13]. Group 4: Future Growth and Strategy - Gushengtang is focused on addressing the distribution of quality medical resources in traditional Chinese medicine through its innovative AI solutions [13]. - The company aims to continuously expand its business boundaries by activating top-tier expert resources and enhancing patient experience through technological and service innovations [13].

Core Insights - The company, Gushengtang, has made significant advancements in the AI field by launching its first "National Medicine AI Avatar" on June 7 and subsequently releasing 10 additional avatars on August 1, covering eight core specialties in traditional Chinese medicine [1][3] - This expansion is a crucial step in Gushengtang's ongoing strategy to integrate AI with traditional Chinese medicine, establishing a standardized industrial system that strengthens its technological and model advantages for commercializing TCM AI [1][3] Group 1: AI Avatar Development - The 10 "National Medicine AI Avatars" are based on the clinical experiences of 10 renowned doctors, ensuring that the AI system aligns closely with expert decision-making processes [3][4] - The AI avatars assist experts in routine diagnostic tasks, allowing them to focus on core decision-making, thereby enhancing the efficiency of top-tier specialists [3][4] - The dual empowerment mechanism of the AI avatars aids young doctors in mastering diagnostic thinking, effectively shortening their learning curve from observation to independent practice [3][4] Group 2: Commercialization and Market Impact - Gushengtang has embedded commercialization logic into the development of the AI avatars, targeting the "online follow-up" scenario to alleviate the scarcity of quality TCM resources and the difficulty in accessing top doctors [4][7] - The "online follow-up" service has shown promising commercial prospects, with significant patient uptake within two weeks of launch, indicating high user acceptance [7] - The AI avatars can theoretically increase expert productivity by over five times, with patients reporting improved communication and overall experience compared to in-person consultations [7][11] Group 3: Technological Innovation - Gushengtang has established a clear and replicable path for creating expert digital avatars, leveraging multi-source heterogeneous data to enhance the AI's capabilities [8][9] - The company has developed a robust technical framework that includes a TCM AI model base and a multi-agent intelligent system, creating significant industry technical barriers [9][10] - The AI avatars have achieved over 86% consistency with expert simulations, demonstrating high accuracy in diagnosis and treatment recommendations [10] Group 4: Future Growth and Strategy - Gushengtang aims to expand its network of expert avatars and create a collaborative AI internet ecosystem for TCM, making quality services accessible to more patients [7][11] - The company plans to innovate its business model to activate top expert resources and enhance patient experience through improved service delivery [11] - By focusing on technological iteration and business model innovation, Gushengtang seeks to address the distribution of quality TCM resources and open new growth pathways in the intelligent development of TCM [11]

Core Insights - The article highlights the significant advancements made by Guoshengtang in the AI field, particularly with the launch of the "National Medicine AI Avatar" which aims to integrate traditional Chinese medicine with AI technology [1][2] - The company has successfully expanded its AI offerings by introducing 10 new AI avatars covering various medical specialties, marking a crucial step in its "Traditional Chinese Medicine + AI" strategy [1][2] Group 1: AI Development and Implementation - The newly launched AI avatars are based on the clinical experiences of 10 renowned traditional Chinese medicine experts, ensuring that the system aligns closely with expert decision-making processes [2][4] - The AI system enhances the efficiency of top experts by assisting with routine diagnostic tasks, allowing them to focus on critical decision-making [2][7] - The dual empowerment mechanism of the AI avatars aids young doctors in mastering diagnostic thinking, thereby shortening their learning curve [2][7] Group 2: Commercialization and Market Impact - Guoshengtang's "online follow-up" service, utilizing the AI avatars, addresses the scarcity of quality traditional Chinese medicine resources and the challenges of medical AI commercialization [4][10] - The initial user feedback indicates a strong acceptance of the online follow-up service, with significant patient engagement reported within two weeks of launch [7][10] - The AI avatars have the potential to increase expert productivity by over five times, enhancing patient experience and communication [7][10] Group 3: Technological Innovation and Collaboration - The company has established a clear and replicable path for creating expert digital avatars, leveraging extensive data from seasoned practitioners [8][9] - Guoshengtang's AI model is built on a robust technical foundation, allowing for efficient data utilization and continuous model updates [8][9] - Collaborations with leading AI companies and research institutions, such as Huawei and Tsinghua University, have strengthened the company's AI capabilities and ecosystem [9][10] Group 4: Future Growth and Strategy - Guoshengtang plans to expand its expert roster and continue developing its AI avatar platform to create a collaborative AI healthcare ecosystem [7][10] - The company aims to innovate its business model to maximize the utilization of top-tier medical resources while enhancing patient care through technology [10]